A pilot study of anti-Tac(FV)-PE38 (LMB-2) immunotoxin for treatment of CD25 positive Hodgkin's disease after fludarabine and cyclophosphamide.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Anti-Tac Fv PE38 conjugate; Cyclophosphamide; Fludarabine
- Indications Hodgkin's disease
- Focus Adverse reactions
- 16 Mar 2012 Biomarkers information updated
- 15 Mar 2012 Planned end date changed from 1 Feb 2009 to 1 May 2008 as reported by ClinicalTrials.gov.
- 15 Mar 2012 Status changed from completed to withdrawn prior to recruitment as reported by ClinicalTrials.gov.